- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01068730
Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects
April 21, 2015 updated by: AstraZeneca
Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets Manufactured by Bristol-Myers Squibb Relative to 500 mg and 1000 mg Diabex (Metformin) Tablets Marketed in Australia by Alphapharm Administered to Healthy Subjects in the Fed State
To demonstrate the bioequivalence of 500 mg and 1000 mg Glucophage tablets manufactured by BMS relative to the respective strengths of 500 mg and 1000 mg Diabex tablets marketed in Australia by Alphapharm in the fed state
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78744
- PPD Development, LP
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women ages 18 to 55 inclusive
- Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations
- Body Mass Index (BMI) of 18 to 32 kg/m², inclusive. BMI = weight (kg)/ [height (m)]²
Exclusion Criteria:
- Any significant acute or chronic medical illness
- Current or recent (within 3 months) gastrointestinal disease
- Any major surgery within 4 weeks of study drug administration
- History of allergy or intolerance to metformin or other similar acting agents
- Prior exposure to metformin within 3 months of study drug administration
- Estimated creatinine clearance (Clcr) of < 80ml/min using the Cockcroft Gault formula
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Treatment A
500 mg metformin (Diabex): Single oral dose of 500 mg metformin (Diabex) tablet administered in the fed condition
|
Tablets, Oral, 500 mg, Once daily, single dose
Other Names:
Tablets, Oral, 1000 mg, Once daily, single dose
Other Names:
|
Other: Treatment B
500 mg metformin (Glucophage™): Single oral dose of 500 mg metformin (Glucophage™) tablet administered in the fed condition
|
Tablets, Oral, 500 mg, Once Daily, single dose
Other Names:
Tablets, Oral, 1000 mg, Once daily, single dose
Other Names:
|
Other: Treatment C
1000 mg metformin (Diabex): Single oral dose of 1000 mg metformin (Diabex) tablet administered in the fed condition
|
Tablets, Oral, 500 mg, Once daily, single dose
Other Names:
Tablets, Oral, 1000 mg, Once daily, single dose
Other Names:
|
Other: Treatment D
1000 mg metformin (Glucophage™): A Single oral dose of 1000 mg metformin (Glucophage™) tablet administered in the fed condition
|
Tablets, Oral, 500 mg, Once Daily, single dose
Other Names:
Tablets, Oral, 1000 mg, Once daily, single dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
Time Frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
|
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.
AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.
|
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
|
Metformin PK Parameter Observed Maximum Plasma Concentration (Cmax)
Time Frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
|
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.
Cmax is the maximum observed concentration of drug substance in plasma.
|
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants With Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)
Time Frame: AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).
|
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment.
SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
|
AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).
|
Participants With Electrocardiogram Abnormalities Considered Clinically Significant or Reported as an AE
Time Frame: From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
|
Clinically significant was determined by the investigator.
ECGs were recorded after participants had been supine for at least 5 minutes.
|
From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
|
Participants With Abnormal Physical Findings
Time Frame: From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).
|
Physical findings that were considered abnormal by the investigator.
|
From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).
|
Participants With Abnormal Vital Sign Findings Reported as an AE
Time Frame: From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).
|
per investigator
|
From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).
|
Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Hematology
Time Frame: From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
|
Clinically significant was determined by the investigator.
|
From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
|
Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Serum Chemistry
Time Frame: From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
|
Clinically significant was determined by the investigator.
|
From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
|
Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis
Time Frame: From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
|
Clinically significant was determined by the investigator.
|
From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metformin Pharmacokinetic (PK) Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)
Time Frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
|
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.
Tmax is the time taken to reach the maximum observed plasma concentration.
|
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
|
Metformin Pharmacokinetic (PK) Parameter Terminal Half-life (T 1/2)
Time Frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
|
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.
T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma
|
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
|
Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])
Time Frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
|
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.
AUC[0-t] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.
|
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (Actual)
April 1, 2010
Study Completion (Actual)
April 1, 2010
Study Registration Dates
First Submitted
February 12, 2010
First Submitted That Met QC Criteria
February 12, 2010
First Posted (Estimate)
February 15, 2010
Study Record Updates
Last Update Posted (Estimate)
May 8, 2015
Last Update Submitted That Met QC Criteria
April 21, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CV181-120
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
DiabeloopUniversity Hospital, Grenoble; AGIR à Dom; Icadom; Centre Hospitalier Annecy Genevois and other collaboratorsCompletedDiabetes Mellitus Type 2 - Insulin-TreatedFrance
Clinical Trials on metformin (Diabex)
-
Seoul National University HospitalCompleted
-
Seoul National University HospitalCompletedHealthy ElderlyKorea, Republic of
-
Handok Inc.CompletedType 2 Diabetes MellitusKorea, Republic of
-
Dong Wha Pharmaceutical Co. Ltd.Completed
-
Seoul National University HospitalDaewoong Pharmaceutical Co. LTD.TerminatedSchizophreniaKorea, Republic of
-
Handok Inc.CompletedType 2 Diabetes MellitusKorea, Republic of
-
Seoul National University HospitalCompletedHuman MicrobiomeKorea, Republic of
-
Kyunghee University Medical CenterSanofi; Korea University Guro Hospital; Hanyang University; The Catholic University... and other collaboratorsCompletedType 2 Diabetes Mellitus | Pancreatic Beta Cell Function | GlucotoxicityKorea, Republic of
-
Astellas Pharma Korea, Inc.Terminated
-
Rush University Medical CenterEli Lilly and CompanyCompletedMetabolic ComplicationsUnited States